Insight

Elie G. Dib: TAPUR study has been presented at the 2024 ASCO Annual Meeting!

ihacares.com

Jun 6, 2024, 14:04

Elie G. Dib: TAPUR study has been presented at the 2024 ASCO Annual Meeting!

Elie G. Dib, Associate Director of the Haematology-Oncology Training Program at Saint Joseph Mercy Hospital, posted on LinkedIn:

“Exciting News!

I’m thrilled to share that TAPUR study on the antitumor activity of Pertuzumab and Trastuzumab in advanced solid tumors with ERBB2/3 alterations has been presented at the 2024 ASCO Annual Meeting!

This research, conducted with the incredible team at Trinity Health MI (Ann Arbor) and other sites across the nation, shows promising results with a disease control rate of 57% and an objective response rate of 29%.

Onward to more advancements in cancer treatment!”

Elie G. Dib

Additional information.
Source: Elie G. Dib/LinkedIn

Abby Gregory Ajjai Shivaram Alva Allison Paige Watson American Society for Clinical Oncology Ann Arbor ASCO ASCO24 cancer treatment Carmen Julia Calfa Deepti Behl Elie G. Dib Elizabeth Garrett-Mayer ERBB2/3 Eugene Ahn Evthokia Hobbs Funda Meric-Bernstam Kathleen J Yost Mehmet Akce Meredith McKean Michael Rothe Navid Hafez Pam K. Mangat pertuzumab Ramya Thota Richard L. Schilsky Saint Joseph Mercy Hospital Susan Halabi TAPUR study Timothy Lewis Cannon trastuzumab Trinity Health MI

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage